Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,401 to 3,420 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Receipt of Risk Stratification Tool Assessment | 86 of 1,018 27 of 1,034 | 5.8 points 3.9 to 7.9 | 2,052 | NCT03702270 The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal |
| Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Penicillin Allergy Label Removal | 45 of 1,018 31 of 1,034 | 1.4 points -0.2 to 3.1 | 2,052 | NCT03702270 The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal |
| COVID Watch vs COVID Watch + Pulse Oximeter: Incidence of Remote Monitoring Escalations to Clinician | 108 of 1,024 242 of 1,025 | -13.1 points -16.3 to -9.8 | 2,049 | NCT04581863 COVID-19 Watch + COVID-19 Pulse |
| COVID Watch vs COVID Watch + Pulse Oximeter: Mortality Among COVID-19 Positive Patients | 3 of 1,024 5 of 1,025 | -0.2 points -0.9 to 0.4 | 2,049 | NCT04581863 COVID-19 Watch + COVID-19 Pulse |
| COVID Watch vs COVID Watch + Pulse Oximeter: deaths from any cause | 3 of 1,024 5 of 1,025 | -0.2 points -0.9 to 0.4 | 2,049 | NCT04581863 COVID-19 Watch + COVID-19 Pulse |
| Zoledronic Acid vs Denosumab: Time to First On-Study Skeletal-Related Event (Superiority) | 372 of 1,020 315 of 1,026 | 5.8 points 1.7 to 9.8 | 2,046 | NCT00321464 A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. |
| Zoledronic Acid vs Denosumab: Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority) | 372 of 1,020 315 of 1,026 | 5.8 points 1.7 to 9.8 | 2,046 | NCT00321464 A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects. |
| Recommended vs Anti-recommended: Inpatient Dialysis | 39 of 1,002 41 of 1,044 | -0.0 points -1.7 to 1.7 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: Proportion of Patients With Progression to a Higher Stage of AKI OR Dialysis OR Death | 190 of 1,002 193 of 1,044 | 0.5 points -2.9 to 3.9 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: Inpatient Mortality | 169 of 1,002 185 of 1,044 | -0.9 points -4.1 to 2.4 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: Progression to Stage 3 AKI | 72 of 1,002 66 of 1,044 | 0.9 points -1.3 to 3.1 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: Progression to Stage 2 AKI | 91 of 1,002 103 of 1,044 | -0.8 points -3.3 to 1.8 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: Discharge on Dialysis | 28 of 1,002 22 of 1,044 | 0.7 points -0.7 to 2.1 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: 14-day Dialysis | 38 of 1,002 37 of 1,044 | 0.2 points -1.4 to 1.9 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: 14-day Mortality | 72 of 1,002 58 of 1,044 | 1.6 points -0.5 to 3.8 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: 30 Day Readmission Rate | 123 of 1,002 187 of 1,044 | -5.6 points -8.7 to -2.5 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: deaths from any cause | 169 of 1,002 185 of 1,044 | -0.9 points -4.1 to 2.4 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Recommended vs Anti-recommended: Chart Documentation of AKI | 442 of 1,002 505 of 1,044 | -4.3 points -8.6 to 0.1 | 2,046 | NCT02786277 Learning Alerts for Acute Kidney Injury |
| Galantamine vs Placebo: serious adverse events | 129 of 1,024 123 of 1,021 | 0.6 points -2.3 to 3.4 | 2,045 | NCT00679627 A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease |
| aQIV vs Comparator QIV: deaths from any cause | 1 of 1,027 0 of 1,016 | 0.1 points -0.3 to 0.5 | 2,043 | NCT05044195 A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age |
Code
curl "https://conductscience.org/api/comparisons/v1?page=171"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=171
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03702270-397bffb7",
"title": "Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Receipt of Risk Stratification Tool Assessment",
"summary": "86 of 1018 against 27 of 1034; risk difference 5.8 points, 95% interval 3.9 to 7.9; NCT03702270, The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal",
"record": "/library/comparisons/NCT03702270-397bffb7",
"nct_id": "NCT03702270",
"kind": "outcome",
"participants": 2052,
"risk_difference": {
"value": 0.05836718562965271,
"lower": 0.03895041823923864,
"upper": 0.07873449714896583
},
"group_1": "86 of 1,018",
"group_2": "27 of 1,034",
"difference": "5.8 points",
"interval": "3.9 to 7.9",
"trial_title": "The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal"
},
{
"id": "NCT03702270-a4dbfe20",
"title": "Penicillin Allergic Floor Patients- Experimental vs Penicillin Allergic Floor Patients- Control: Penicillin Allergy Label Removal",
"summary": "45 of 1018 against 31 of 1034; risk difference 1.4 points, 95% interval -0.2 to 3.1; NCT03702270, The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal",
"record": "/library/comparisons/NCT03702270-a4dbfe20",
"nct_id": "NCT03702270",
"kind": "outcome",
"participants": 2052,
"risk_difference": {
"value": 0.014223664560160821,
"lower": -0.0022511218563102085,
"upper": 0.031117035448879116
},
"group_1": "45 of 1,018",
"group_2": "31 of 1,034",
"difference": "1.4 points",
"interval": "-0.2 to 3.1",
"trial_title": "The Effect of Providing Stratification of Low Risk Penicillin Allergies on Penicillin Allergy Label Removal"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=172",
"request_id": "VDM-G8ip4mFGig5V"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant